Sundry Photography
- The U.S. FDA has granted priority review to Gilead Sciences’ (NASDAQ:GILD) application for a twice-yearly injectable version of its HIV drug Sunlenca (lenacapavir).
- The FDA action date is June 19, 2025. Sunlenca was previously granted Breakthrough Therapy Designation for PrEP.
